Moleculin Biotech (NASDAQ:MBRX) Announces Quarterly Earnings Results

Moleculin Biotech (NASDAQ:MBRX) issued its quarterly earnings results on Friday. The company reported ($9.59) EPS for the quarter, missing the consensus estimate of ($8.87) by ($0.72), FiscalAI reports.

Moleculin Biotech Trading Down 1.7%

Shares of Moleculin Biotech stock traded down $0.14 on Friday, reaching $7.92. 9,899 shares of the company were exchanged, compared to its average volume of 33,123. The stock has a fifty day moving average price of $10.05 and a 200-day moving average price of $37.12. The firm has a market capitalization of $8.16 million, a price-to-earnings ratio of -0.06 and a beta of 2.11. Moleculin Biotech has a fifty-two week low of $3.23 and a fifty-two week high of $229.40.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the stock. Wall Street Zen lowered shares of Moleculin Biotech from a “sell” rating to a “strong sell” rating in a research report on Saturday, November 7th. HC Wainwright dropped their target price on shares of Moleculin Biotech to $60.00 and set a “buy” rating on the stock in a report on Friday, August 28th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Moleculin Biotech in a research note on Thursday, October 15th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $60.00.

About Moleculin Biotech

Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company focused on developing treatments for cancers and other serious diseases. The company uses its proprietary technology platforms to design drug candidates intended to address treatment resistance, improve drug delivery, and target biological pathways involved in disease progression. Moleculin’s lead program is Annamycin, a liposomal formulation of the anthracycline doxorubicin being investigated for acute myeloid leukemia and soft-tissue sarcoma.